Trial Profile
Non-Comparative, Multi-Cohort, Single Arm, Open-Label, Phase 2 Study of Nivolumab (BMS-936558) in classical Hodgkin Lymphoma (cHL) Subjects
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Nov 2023
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Dacarbazine; Doxorubicin; Vinblastine
- Indications Hodgkin's disease
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms CheckMate 205
- Sponsors Bristol-Myers Squibb
- 09 Feb 2023 This trial has been completed in Austria, according to European Clinical Trials Database record. (27 Dec 2022)
- 20 Jan 2023 Status changed from active, no longer recruiting to completed.
- 14 Nov 2022 Planned End Date changed from 1 Nov 2022 to 30 Nov 2022.